F058 Advanced Management Strategies for Hidradenitis Suppurativa
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Hidradenitis suppurativa (HS) is one of the most severe and challenging diseases dermatologists treat. In this session the audience will learn treatment strategies for patients with both early-stage and more advanced disease using a range of treatment options. Importantly, strategies for when to select modalities such as antibiotics, hormonal therapy, immunomodulators, laser, and office-based procedures and and how to combine them appropriately will be highlighted. This will include treatment of pain and other common comorbidities. Emphasis will also be placed on the efficient management of individual patients and for those developing high-volume specialty clinics.
LEARNING OBJECTIVES
Recognize how to optimize the treatment of early stage disease
Predict and mange challenges that may arise during surgical procedures for patients with HS in the office setting
Manage individual patients and/or large populations of patients with HS efficiently and effectively
SCHEDULE
9:00 PM
Management of early stage HS
Richard H Flowers, MD, FAAD
9:20 PM
Managing Pain and Comorbidities
Natalie Fragoso, MD, FAAD
9:40 PM
What's New in Biologics and Small Molecules
Martina J Porter, MD, FAAD
10:00 PM
Q&A
Richard H Flowers, MD, FAAD, Natalie Fragoso, MD, FAAD, Martina J Porter, MD, FAAD
10:10 PM
Surgical Pearls and Pitfalls
Christopher John Sayed, MD, FAAD
10:30 PM
Efficiently Managing HS Patients Individually or in Specialty Clinics
Steven Daniel Daveluy, MD, FAAD
SPEAKERS
Steven Daniel Daveluy, MD, FAAD
Richard H Flowers, MD, FAAD
Natalie Fragoso, MD, FAAD
Martina J Porter, MD, FAAD
Christopher John Sayed, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Steven Daniel Daveluy, MD, FAAD
AbbVie – Speaker(Honoraria); MoonLake Immunotherapeutics – Investigator(Grants/Research Funding); Novartis – Speaker(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding); Sanofi – Investigator(Grants/Research Funding); UCB – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Honoraria);
Richard H Flowers, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Acelyrin – Investigator(Grants/Research Funding); argenx – Advisory Board(Fees); Bristol-Myers Squibb – Advisory Board(Fees); Concert Pharmaceuticals – Investigator(Grants/Research Funding); Janssen Pharmaceuticals, Inc – Advisory Board(Fees); Regeneron Pharmaceuticals, Inc. – Investigator(Grants/Research Funding);
Natalie Fragoso, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Acelyrin – Investigator(Grants/Research Funding); Amgen – Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Investigator(Grants/Research Funding); Target-Derm – Investigator(Grants/Research Funding); UCB Pharma – Consultant (1099 relationship)(Fees);
Martina J Porter, MD, FAAD
AbbVie – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Alumis – Consultant(Fees); AnaptysBio – Investigator(Grants/Research Funding); Bayer – Investigator(Grants/Research Funding); Beth Israel Deaconess Medical Center – Other(Patent royalties or other compensation for Intellectual Property Rights); Bristol-Myers Squibb – Investigator(Grants/Research Funding); Eli Lilly – Consultant (1099 relationship)(No Compensation Received); Eli Lilly and Company – Investigator(Grants/Research Funding); FIDE – Consultant (1099 relationship)(Fees); Incyte Corporation – Consultant(Fees), Investigator(Grants/Research Funding); Janssen Pharmaceuticals, Inc – Investigator(Grants/Research Funding); Janssen Research & Development, LLC – Consultant(Fees); Mirador – Investigator(Grants/Research Funding); Moonlake – Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); National Psoriasis Foundation – Speaker(Honoraria); Novartis – Consultant(Fees), Investigator(Grants/Research Funding); Oasis Pharmaceuticals – Investigator(Grants/Research Funding); Pfizer Inc. – Consultant(Fees), Investigator(Grants/Research Funding); Prometheus Laboratories, Inc. – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding); Sanofi – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Sonoma Biotherapeutics – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Trifecta Clinical – Consultant(Fees); UCB – Consultant(Fees), Investigator(Grants/Research Funding); Zura Bio – Consultant (1099 relationship)(Fees);
Christopher John Sayed, MD, FAAD
AbbVie – Advisory Board(Fees), Investigator(Fees), Speaker(Fees); Alumis – Consultant(Fees); AstraZeneca – Consultant (1099 relationship)(Fees); ChemoCentryx – Investigator(Grants/Research Funding); Eli Lilly – Stockholder Public Company(Stock); Incyte – Consultant (1099 relationship)(Fees); Incyte Corporation – Investigator(Grants/Research Funding); InflaRx – Consultant(Fees), Investigator(Grants/Research Funding); Novartis – Investigator(Fees), Speaker(Honoraria); Sanofi – Consultant (1099 relationship)(Fees); UCB – Advisory Board(Honoraria), Consultant(Fees), Investigator(Grants/Research Funding);